Risk factors for developing active tuberculosis after the treatment of latent tuberculosis in adults infected with human immunodeficiency virus

Open Forum Infectious Diseases

Volumn 2, Issue 1, 2015, Pages

  Amoakwa, Kojo ^a   Martinson, Neil A ^b,c   Moulton, Lawrence H ^a   Barnes, Grace L ^c   Msandiwa, Reginah ^b   Chaisson, Richard E ^a,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Baseline; HIV infected adults; Latent tuberculosis; Preventive therapy; Risk

Indexed keywords

ISONIAZID; ISONIAZID PLUS RIFAMPICIN; RIFAPENTINE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SELF REPORT; SMOKING; TUBERCULIN TEST; VIRUS LOAD; WESTERN BLOTTING;

EID: 84978327811     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu120     Document Type: Article

References (12)

1. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009-21.
2. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; 1: CD000171.
3. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365:11-20.
4. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974; 99:131-8.
5. Leung CC, Yew WW, Au KF, et al. A strong tuberculin reaction in primary school children predicts tuberculosis in adolescence. Pediatr Infect Dis J 2012; 31:150-3.
6. Larson EM, O'Donnell M, Chamblee S, et al. Dual skin tests with Mycobacterium avium sensitin and PPD to detect misdiagnosis of latent tuberculosis infection. Int J Tuberc Lung Dis 2011; 15:1504-9, i.
7. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365:2155-66.
8. Narasimhan P, Wood J, Macintyre CR, et al. Risk factors for tuberculosis. Pulm Med 2013; 2013:828939.
9. Hanrahan CF, Golub JE, Mohapic L, et al. Body mass index and risk of tuberculosis and death. AIDS 2009; 424:1501-8.
10. Zenteno-Cuevas R, Montes-Villasenor E, Morales-Romero J, et al. Coinfection and risk factors of tuberculosis in a Mexican HIV+ population. Rev Soc Bras Med Trop 2011; 44:282-5.
11. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122:573-9.
12. Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-70.